2024. By the end of the decade, the new standard will be mandatory in most major global regions.</p> <p>For pharmaceutical manufacturers making the transition to eCTD 4.0, now is a good time to review the workflows associated with regulatory publishing. After all, much has changed since the International Council for Harmonisation (ICH) finalized eCTD 3.0 in October of 2003.</p> <p>Current requirements for regulatory submissions are more stringent, both to ensure patient safety and product efficacy but also to address emerging technologies such as wearable medical devices and digital therapeutics. As a result, today&rsquo;s submissions are thousands of pages long.</p> <p>The additional length of submissions is enough on its own to create data management and documentation challenges. Data silos further compound the problems. As different business units are called upon to provide data to support submissions, from research and development to medical affairs to pharmacovigilance, silos present a significant hurdle to integrating data from disparate sources across the enterprise and meeting submission deadlines.</p> <p>Many organizations have attempted to address this issue by adding staff. However, legacy manual processes for creating, tracking, and publishing regulatory documentation are too time-consuming to be solved through increased personnel alone. Applying automation to the regulatory submission process brings a twofold benefit of supporting compliance in a modern regulatory landscape &ndash; including support for eCTD 4.0 &ndash; while improving data consistency and streamlining the application and submission process.</p> <p>Automation technology benefits the regulatory publishing process in five key ways:</p> <p><strong>Obtain data directly from its source.</strong> Artificial intelligence (AI) and machine learning (ML) technologies make it possible to aggregate data from its source application, harmonize it, and import it directly into the regulatory document for which it is needed. Natural language processing (NLP) technology can be applied to unstructured data sources as well, saving significant time and resources typically devoted to data harmonization.</p> <p><strong>Adopt a new data management framework.</strong> AI, ML, and NLP technologies enable the adoption of a more strategic and holistic data management framework. By managing data in the same manner that it is used to complete regulatory applications, and by updating this framework as regulations change, data is readily usable once it has been obtained from its source.</p> <p><strong>Reuse approved data where applicable.</strong> Once data has been approved for use in one regulatory application, automation makes it possible for data (and other relevant content) to populate additional applications, authorizations, or updates. This addresses a feature new to the eCTD 4.0 standard, which now allows many-to-one and many-to-many data replacements.</p> <p><strong>Provide notification of submission requests.</strong> As contributions from a growing number of stakeholders are required for each regulatory submission, timely responses to requests for information or necessary approvals are critical for meeting application deadlines. Automated assignments and notifications eliminate the need to send messages or make phone calls when action is required, removing bottlenecks from the process of completing submissions and significantly reducing delays. </p> <p><strong>Apply changes globally.</strong> Automation also enables bulk updates, both within the same application as well as across applications and sequences. This applies to the content of the document, to comments or updated due dates, and even to structured content (such as labeling) that is tied to a product but may not be part of a regulatory submission. This ensures data continuity throughout the organization, which saves time and resources for organizations applying for regulatory approval for existing products in new regions or for new products similar to those already on the market.</p> <p>Amid the transition to eCTD 4.0, it&rsquo;s critical for pharmaceutical manufacturers to work with partners who are prepared for the new standard and understand how to automate and streamline regulatory publishing workflows at each stage of the process. Through automation, organizations can replace legacy manual processes, improving data quality while speeding up the regulatory publishing process and bringing products to market faster.</p> <p>For more information, please visit the <a href=https://www.iqvia.com/blogs/2022/09/"~/link.aspx?_id=120D4EC88E814641AB9A3F1310F07553&amp;_z=z%22>IQVIA RIM Smart</a>&nbsp;page or send a note to <a href=https://www.iqvia.com/blogs/2022/09/"mailto:RegulatoryTechnology@iqvia.com">RegulatoryTechnology@iqvia.com.

" /> 2024. By the end of the decade, the new standard will be mandatory in most major global regions.</p> <p>For pharmaceutical manufacturers making the transition to eCTD 4.0, now is a good time to review the workflows associated with regulatory publishing. After all, much has changed since the International Council for Harmonisation (ICH) finalized eCTD 3.0 in October of 2003.</p> <p>Current requirements for regulatory submissions are more stringent, both to ensure patient safety and product efficacy but also to address emerging technologies such as wearable medical devices and digital therapeutics. As a result, today&rsquo;s submissions are thousands of pages long.</p> <p>The additional length of submissions is enough on its own to create data management and documentation challenges. Data silos further compound the problems. As different business units are called upon to provide data to support submissions, from research and development to medical affairs to pharmacovigilance, silos present a significant hurdle to integrating data from disparate sources across the enterprise and meeting submission deadlines.</p> <p>Many organizations have attempted to address this issue by adding staff. However, legacy manual processes for creating, tracking, and publishing regulatory documentation are too time-consuming to be solved through increased personnel alone. Applying automation to the regulatory submission process brings a twofold benefit of supporting compliance in a modern regulatory landscape &ndash; including support for eCTD 4.0 &ndash; while improving data consistency and streamlining the application and submission process.</p> <p>Automation technology benefits the regulatory publishing process in five key ways:</p> <p><strong>Obtain data directly from its source.</strong> Artificial intelligence (AI) and machine learning (ML) technologies make it possible to aggregate data from its source application, harmonize it, and import it directly into the regulatory document for which it is needed. Natural language processing (NLP) technology can be applied to unstructured data sources as well, saving significant time and resources typically devoted to data harmonization.</p> <p><strong>Adopt a new data management framework.</strong> AI, ML, and NLP technologies enable the adoption of a more strategic and holistic data management framework. By managing data in the same manner that it is used to complete regulatory applications, and by updating this framework as regulations change, data is readily usable once it has been obtained from its source.</p> <p><strong>Reuse approved data where applicable.</strong> Once data has been approved for use in one regulatory application, automation makes it possible for data (and other relevant content) to populate additional applications, authorizations, or updates. This addresses a feature new to the eCTD 4.0 standard, which now allows many-to-one and many-to-many data replacements.</p> <p><strong>Provide notification of submission requests.</strong> As contributions from a growing number of stakeholders are required for each regulatory submission, timely responses to requests for information or necessary approvals are critical for meeting application deadlines. Automated assignments and notifications eliminate the need to send messages or make phone calls when action is required, removing bottlenecks from the process of completing submissions and significantly reducing delays. </p> <p><strong>Apply changes globally.</strong> Automation also enables bulk updates, both within the same application as well as across applications and sequences. This applies to the content of the document, to comments or updated due dates, and even to structured content (such as labeling) that is tied to a product but may not be part of a regulatory submission. This ensures data continuity throughout the organization, which saves time and resources for organizations applying for regulatory approval for existing products in new regions or for new products similar to those already on the market.</p> <p>Amid the transition to eCTD 4.0, it&rsquo;s critical for pharmaceutical manufacturers to work with partners who are prepared for the new standard and understand how to automate and streamline regulatory publishing workflows at each stage of the process. Through automation, organizations can replace legacy manual processes, improving data quality while speeding up the regulatory publishing process and bringing products to market faster.</p> <p>For more information, please visit the <a href=https://www.iqvia.com/blogs/2022/09/"~/link.aspx?_id=120D4EC88E814641AB9A3F1310F07553&amp;_z=z%22>IQVIA RIM Smart</a>&nbsp;page or send a note to <a href=https://www.iqvia.com/blogs/2022/09/"mailto:RegulatoryTechnology@iqvia.com">RegulatoryTechnology@iqvia.com.

" />
Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
How automation supports regulatory publishing amid the transition to eCTD 4.0
Jason Berning, Associate Director, IQVIA Regulatory Technology
Sep 21, 2022
  • Blogs
  • How automation supports regulatory publishing amid the transition to eCTD 4.0

Around the world, regulatory bodies are preparing for the transition to version 4.0 of the electronic common technical document (eCTD) for submission of applications, amendments, and other reports. Japan is already accepting electronic data submissions in eCTD 4.0, while Canada and the United States will accept eCTD 4.0 next year and Switzerland and the European Union will accept eCTD 4.0 starting in 2024. By the end of the decade, the new standard will be mandatory in most major global regions.

For pharmaceutical manufacturers making the transition to eCTD 4.0, now is a good time to review the workflows associated with regulatory publishing. After all, much has changed since the International Council for Harmonisation (ICH) finalized eCTD 3.0 in October of 2003.

Current requirements for regulatory submissions are more stringent, both to ensure patient safety and product efficacy but also to address emerging technologies such as wearable medical devices and digital therapeutics. As a result, today’s submissions are thousands of pages long.

The additional length of submissions is enough on its own to create data management and documentation challenges. Data silos further compound the problems. As different business units are called upon to provide data to support submissions, from research and development to medical affairs to pharmacovigilance, silos present a significant hurdle to integrating data from disparate sources across the enterprise and meeting submission deadlines.

Many organizations have attempted to address this issue by adding staff. However, legacy manual processes for creating, tracking, and publishing regulatory documentation are too time-consuming to be solved through increased personnel alone. Applying automation to the regulatory submission process brings a twofold benefit of supporting compliance in a modern regulatory landscape – including support for eCTD 4.0 – while improving data consistency and streamlining the application and submission process.

Automation technology benefits the regulatory publishing process in five key ways:

Obtain data directly from its source. Artificial intelligence (AI) and machine learning (ML) technologies make it possible to aggregate data from its source application, harmonize it, and import it directly into the regulatory document for which it is needed. Natural language processing (NLP) technology can be applied to unstructured data sources as well, saving significant time and resources typically devoted to data harmonization.

Adopt a new data management framework. AI, ML, and NLP technologies enable the adoption of a more strategic and holistic data management framework. By managing data in the same manner that it is used to complete regulatory applications, and by updating this framework as regulations change, data is readily usable once it has been obtained from its source.

Reuse approved data where applicable. Once data has been approved for use in one regulatory application, automation makes it possible for data (and other relevant content) to populate additional applications, authorizations, or updates. This addresses a feature new to the eCTD 4.0 standard, which now allows many-to-one and many-to-many data replacements.

Provide notification of submission requests. As contributions from a growing number of stakeholders are required for each regulatory submission, timely responses to requests for information or necessary approvals are critical for meeting application deadlines. Automated assignments and notifications eliminate the need to send messages or make phone calls when action is required, removing bottlenecks from the process of completing submissions and significantly reducing delays.

Apply changes globally. Automation also enables bulk updates, both within the same application as well as across applications and sequences. This applies to the content of the document, to comments or updated due dates, and even to structured content (such as labeling) that is tied to a product but may not be part of a regulatory submission. This ensures data continuity throughout the organization, which saves time and resources for organizations applying for regulatory approval for existing products in new regions or for new products similar to those already on the market.

Amid the transition to eCTD 4.0, it’s critical for pharmaceutical manufacturers to work with partners who are prepared for the new standard and understand how to automate and streamline regulatory publishing workflows at each stage of the process. Through automation, organizations can replace legacy manual processes, improving data quality while speeding up the regulatory publishing process and bringing products to market faster.

For more information, please visit the IQVIA RIM Smart page or send a note to RegulatoryTechnology@iqvia.com.

You may also be interested in

Scientific Poster
Leveling up RWE adoption by US payers: The path towards optimizing its use in drug value assessments
White Paper
eCTD 4.0 Implementation: Including Understanding of Regional Differences and Benefits
Audio
Podcast 1: DEA Suspicious Order Monitoring
Blog
Preparing for the new and improved eCTD regulatory submission standard
White Paper
Elevating the Quality of QMS in Life Sciences: The Age of Digital eQMS
White Paper
Smart Factory - Smart Quality Management
Prev
Next

Related solutions

Regulatory Compliance

Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.

Contact Us